QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.061614v1 308/3/1121    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Treiber, A. Articles by Clozel, M. Search for Related Content PubMed PubMed Citation Articles by Treiber, A. Articles by Clozel, M.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat

Department of Preclinical Pharmacokinetics and Metabolism, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

In clinical trials, a significant interaction between the endothelin receptor antagonist bosentan and the immunosuppressant cyclosporin A was observed, which could not be rationalized in terms of inhibition of drug-metabolizing enzymes. We present here a study performed in rats investigating the mechanisms underlying this interaction, including the inhibition of active drug transport processes as part of the gastrointestinal absorption and disposition into the liver. In vitro, the majority of bosentan uptake into liver cells was shown to depend on active transport and to be efficiently inhibited by cyclosporin A. All known members of the organic anion transporting polypeptide (oatp) transport protein family expressed in rat liver, i.e., oatp1, oatp2, and oatp4, were shown to be involved in the uptake of bosentan. Results from both series of experiments point to inhibition of active bosentan uptake into the liver by cyclosporin A as the major underlying mechanism for this pharmacokinetic interaction that is in line with reports on other oatp-transported drugs. Significant contributions of other mechanisms such as inhibition of mdr1-mediated drug efflux during gastrointestinal absorption, inhibition of bosentan metabolism, or inhibition of hepatobiliary excretion seemed to be unlikely. The interaction between bosentan and cyclosporin A is a rare example of a pharmacokinetic interaction, which can mostly be attributed to the inhibition of transport processes in the liver. It also demonstrates that inhibition of uptake into the liver might become rate-limiting in the overall elimination process even for compounds whose clearance is dependent on metabolism. The relevance of these findings in the rat for clinical use remains to be explored. It is, however, clear that inhibition of CYP3A4-mediated metabolism by cyclosporin A alone is insufficient to explain the increased bosentan concentrations and that inhibition of hepatocellular uptake offers an attractive mechanistic alternative also in human.

Address correspondence to: Dr. Alexander Treiber, Department of Preclinical Pharmacokinetics and Metabolism, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, 4123 Allschwil, Switzerland. E-mail: alexander.treiber{at}actelion.com

This article has been cited by other articles:

				Y. Shitara, Y. Nagamatsu, S. Wada, Y. Sugiyama, and T. Horie Long-Lasting Inhibition of the Transporter-Mediated Hepatic Uptake of Sulfobromophthalein by Cyclosporin A in Rats Drug Metab. Dispos., June 1, 2009; 37(6): 1172 - 1178. [Abstract] [Full Text] [PDF]

				S. Eyal, F. S. Chung, M. Muzi, J. M. Link, D. A. Mankoff, A. Kaddoumi, F. O'Sullivan, M. F. Hebert, and J. D. Unadkat Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate J. Nucl. Med., May 1, 2009; 50(5): 798 - 806. [Abstract] [Full Text] [PDF]

				A. Poirier, T. Lave, R. Portmann, M.-E. Brun, F. Senner, M. Kansy, H.-P. Grimm, and C. Funk Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model Drug Metab. Dispos., December 1, 2008; 36(12): 2434 - 2444. [Abstract] [Full Text] [PDF]

				Y.-J. He, W. Zhang, J.-H. Tu, J. Kirchheiner, Y. Chen, D. Guo, Q. Li, Z.-Y. Li, H. Chen, D.-L. Hu, et al. Hepatic Nuclear Factor 1{alpha} Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin Drug Metab. Dispos., August 1, 2008; 36(8): 1453 - 1456. [Abstract] [Full Text] [PDF]

				A. Treiber, R. Schneiter, S. Hausler, and B. Stieger Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil Drug Metab. Dispos., August 1, 2007; 35(8): 1400 - 1407. [Abstract] [Full Text] [PDF]

				C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.-L. Ungell, and J. Karlsson Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines Drug Metab. Dispos., August 1, 2007; 35(8): 1333 - 1340. [Abstract] [Full Text] [PDF]

				M. G. Soars, K. Grime, J. L. Sproston, P. J. H. Webborn, and R. J. Riley Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo Drug Metab. Dispos., June 1, 2007; 35(6): 859 - 865. [Abstract] [Full Text] [PDF]

				H. Xiong, R. A. Carr, C. S. Locke, D. A. Katz, R. Achari, T. T. Doan, P. Wang, J. R. Jankowski, and D. J. Sleep Dual Effects of Rifampin on the Pharmacokinetics of Atrasentan J. Clin. Pharmacol., April 1, 2007; 47(4): 423 - 429. [Abstract] [Full Text] [PDF]

				J. L. Lam, H. Okochi, Y. Huang, and L. Z. Benet IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY Drug Metab. Dispos., August 1, 2006; 34(8): 1336 - 1344. [Abstract] [Full Text] [PDF]

				Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 762 - 771. [Abstract] [Full Text] [PDF]

				D. C. Kemp, M. J. Zamek-Gliszczynski, and K. L. R. Brouwer Xenobiotics Inhibit Hepatic Uptake and Biliary Excretion of Taurocholate in Rat Hepatocytes Toxicol. Sci., February 1, 2005; 83(2): 207 - 214. [Abstract] [Full Text] [PDF]